

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 300,000 employees have dedicated themselves to the service of health.

FRESENIUS GROUP IN FIGURES

€ in millions	H1/23	H1/22	Change	FY/22
Revenue and Earnings				
Revenue	20,584	19,738	4%	40,840
EBIT ¹	1,864	2,003	-7%	4,004
Net income ^{1,2}	764	913	-16%	1,729
Earnings per share in € ^{1,2}	1.36	1.63	-17%	3.08
Balance sheet and cash flow				
Total assets	76,413		0%	76,415
Non-current assets	57,108		-2%	58,136
Equity ³	31,430		-2%	32,218
Equity ratio ³	41.1%			42.2%
Net debt/EBITDA ^{1,4}	3.88x			3.65x
Investments ⁵	844	1,210	-30%	3,465
Operating cash flow	1,361	1,118	22%	4,198
Operating cash flow in % of sales	6.6%	5.7%		10.3%
Profitability				
EBIT margin ¹	9.1%	10.1%		9.8%
Return on equity after taxes (ROE) ^{1,2}	7.9%	9.0%		8.5%
Return on operating assets (ROOA) ¹	5.3%			5.7%
Return on invested capital (ROIC) ¹	4.6%			5.1%
Employees	315,233			316,920

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA


³ Including noncontrolling interests

⁴ At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures

⁵ Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of June 30, 2023

OPERATING COMPANIES

€ in millions		H1/23	H1/22	Change	FY/22
FRESENIUS KABI	Revenue	3,992	3,743	7%	7,850
	EBIT ¹	574	564	2%	1,080
FRESENIUS HELIOS	Revenue	6,179	5,856	6%	11,716
	EBIT ¹	622	609	2%	1,185


¹ Before special items

INVESTMENT COMPANIES

€ in millions		H1/23	H1/22	Change	FY/22
FRESENIUS MEDICAL CARE	Revenue	9,529	9,305	2%	19,398
	EBIT ¹	755	675	12%	1,512
FRESENIUS VAMED	Revenue	1,114	1,075	4%	2,359
	EBIT ¹	-47	19	--	20

¹ Before special items


REVENUE BY REGION



H1/23: €20.6 billion


- ▶ **Fresenius Kabi** specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids.
- ▶ **Fresenius Helios** is Europe's leading private health care provider. The company comprises Helios Germany, Helios Spain and Helios Fertility. Helios Germany operates 87 hospitals, around 240 outpatient centers, 27 occupational health centers and 6 prevention centers. Helios Spain operates 50 hospitals, around 100 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with 8 hospitals and as a provider of medical diagnostics. Helios Fertility offers a wide spectrum of state-of-the-art services in the field of fertility treatments.
- ▶ **Fresenius Medical Care** is the world's largest provider of products and services for individuals with renal diseases. As of June 30, 2023, Fresenius Medical Care was treating approximately 344,000 patients in 4,050 dialysis clinics. Dialyzers and dialysis machines are among the most important product lines. In addition, Fresenius Medical Care offers dialysis-related services.
- ▶ **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management to total operational management.

REVENUE BY BUSINESS SEGMENT




H1/23: €20.6 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT OF DIVIDENDS IN €



GROUP OUTLOOK 2023

	FY/22 Base	Targets 2023
Revenue, growth (organic) excl. FMC	€21,532 million	Mid single-digit %-growth
EBIT growth ¹ (cc) excl. FMC	€2,187 million	Broadly flat to mid-single-digit %-decline

¹ Before special items

For the outlook of the business segments please see the Investor News of August 2, 2023.

FRESENIUS SHARE / ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (June 30, 2023)	563,237,277
Market capitalization (June 30, 2023)	€14.3 billion

ANALYST RECOMMENDATIONS


Equal-weight/ Hold/
Neutral 37%



Buy/Outperform/
Overweight 63%

As of July 25, 2023

FINANCING MIX OF THE FRESENIUS GROUP



June 30, 2023: ~€28.2 billion

FINANCIAL CALENDAR

	Dates
Report on 1st-3rd quarter 2023	November 2, 2023

Please note that these dates could be subject to modifications.
www.fresenius.com/events-and-roadshows

CONTACT



Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.de

Markus Georgi
Senior Vice President
Investor Relations
Telephone: +49 (0) 61 72/6 08-24 85
Telefax: +49 (0) 61 72/6 08-24 88

Follow us on Social Media:

 [linkedin.com/company/fresenius-investor-relations](https://www.linkedin.com/company/fresenius-investor-relations)
 twitter.com/Fresenius_IR

For more information please see the imprint on our corporate website.